title: Interaction between neurokinin A, VIP, prostanoids, and enteric nerves in regulation of duodenal function.
abstract: Neurokinin A (NKA) induces duodenal motility and increases mucosal permeability and bicarbonate secretion in the in situ perfused duodenum in anesthetized rats. In the present study, the NKA-induced increase in mucosal permeability was potentiated by luminal perfusion with lidocaine and diminished by vasoactive intestinal peptide (VIP) but unaltered by elevated intraluminal pressure. Elevation of intraluminal pressure, however, potentiated the stimulatory effect of NKA on bicarbonate secretion. In contrast, the tachykinin decreased the rate of alkalinization in rats subjected to elevated intraluminal pressure and treated with indomethacin. Similarly, NKA partially inhibited the VIP-stimulated bicarbonate secretion. Luminal lidocaine did not affect the secretory response to NKA. The motility induced by NKA was unaffected by VIP or lidocaine but decreased by elevated intraluminal pressure. It is concluded that the NKA-induced increase in duodenal mucosal bicarbonate secretion is independent of neurons and possibly mediated by prostanoids. The increase in mucosal permeability in response to NKA may be suppressed by mucosal nerves, perhaps utilizing VIP as one of the transmitters.
authors.affiliation: Department of Physiology, Biomedical Center, Uppsala University, S-751 23 Uppsala, Sweden.
authors.forename: A
authors.initials: A
authors.lastname: Hällgren
authors.forename: G
authors.initials: G
authors.lastname: Flemström
authors.forename: O
authors.initials: O
authors.lastname: Nylander
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001639:Bicarbonates / Q000378:metabolism; D002860:Chromium Radioisotopes / Q000493:pharmacokinetics; D004386:Duodenum / Q000187:drug effects / Q000294:innervation / Q000502:physiology*; D004492:Edetic Acid / Q000493:pharmacokinetics; D005769:Gastrointestinal Motility / Q000187:drug effects / Q000502:physiology*; D007213:Indomethacin / Q000494:pharmacology; D007262:Infusions, Intravenous; D007408:Intestinal Absorption / Q000187:drug effects / Q000502:physiology*; D007413:Intestinal Mucosa / Q000187:drug effects / Q000502:physiology*; D008012:Lidocaine / Q000008:administration & dosage / Q000494:pharmacology; D008297:Male; D008657:Metabolic Clearance Rate; D009130:Muscle, Smooth / Q000187:drug effects / Q000294:innervation / Q000502:physiology*; D015288:Neurokinin A / Q000008:administration & dosage / Q000494:pharmacology*; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D011312:Pressure; D011453:Prostaglandins / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013564:Sympathetic Nervous System / Q000502:physiology; D014660:Vasoactive Intestinal Peptide / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D001639:Bicarbonates; D002860:Chromium Radioisotopes; D011453:Prostaglandins; D014660:Vasoactive Intestinal Peptide; D015288:Neurokinin A; D008012:Lidocaine; D004492:Edetic Acid; D007213:Indomethacin